Navigation Links
Ohio State researchers design a viral vector to treat a genetic form of blindness
Date:11/2/2011

COLUMBUS, Ohio Researchers at Ohio State University Medical Center and Nationwide Children's Hospital have developed a viral vector designed to deliver a gene into the eyes of people born with an inherited, progressive form of blindness that affects mainly males.

The vector is part of a clinical trial investigating the use of gene therapy to cure choroideremia, a disease that affects an estimated 100,000 people worldwide. The trial is being conducted by researchers at the University of Oxford in England.

The vector was designed by Dr. Matthew During, professor of molecular virology, immunology and medical genetics and of neuroscience and neurological surgery at Ohio State, in collaboration with Robert MacLaren, professor of ophthalmology at the University of Oxford, who also leads the trial.

Researcher Dr. K. Reed Clark, director of the Clinical Manufacturing Facility at the Center for Gene Therapy, Nationwide Children's Hospital, and his team produced the clinical-grade vector that is administered to patients in the trial.

During, who is also a visiting professor of translational neuroscience at Oxford, was in the operating room during the pioneering surgery. "I and my colleagues are excited about contributing to this significant medical breakthrough," During says. "We have worked for many years to engineer and optimize viruses to safely deliver genes to humans, and the eye is an ideal target in many ways. The clinical vector manufacturing facility at Nationwide Children's Hospital is outstanding, and Dr. Clark and his team deserve congratulations for providing a clinical vector that for the first time offers these patients the possibility of an effective therapy."

During and his colleagues designed the viral vector to infect the light-sensitive photoreceptor cells that line the back of the eye and make up the retina. Choroideremia causes a degeneration of these photosensitive retinal cells and progressive blindness. The diagnosis is usually made in childhood and leads to blindness by around age 45

"This trial represents the first attempt to treat this disease and the first time that gene therapy has been directed towards the photoreceptor cells of the human retina," During says. "We believe it holds great promise for the treatment of other genetic causes of blindness such as retinitis pigmentosa."

The trial's 12 patients will be treated in one eye. It will take 24 months to know whether the gene-therapy treatment has stopped the degeneration. The trial builds on gene-therapy research performed in collaboration with Professor Miguel Seabra at Imperial College London, along with During and Clark at Ohio State.

"This disease has been recognized as an incurable form of blindness for over a hundred years," MacLaren says. "I cannot describe the excitement in thinking that we have designed a genetic treatment that could potentially stop it in its tracks with one single injection."


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. More radionuclide therapy is better for prostate cancer patients
2. Preterm birth rate shows three year improvement in most states
3. Michigan State University tackles health needs of an aging statewide population
4. New findings could lower risk of suicide in men with prostate cancer
5. Florida poll: Research important for state economy, jobs
6. Wayne State to develop a computer-delivered intervention for alcohol use during pregnancy
7. You are what you eat: Low fat diet with fish oil slowed growth of human prostate cancer cells
8. Wayne State University study of heroin users to examine links between stress, drug use
9. Henry Ford Hospital first in United States to offer MKTP surgery as treatment option for vitiligo
10. Researchers have found evidence for the existence of a hypnotic state
11. Mayo Clinic study: PSA test valuable in predicting biopsy need, low-risk prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... ... a half of planning the Multiple Pathways of Recovery Conference , CCAR is pleased ... held May 2 -4, 2016 at the Mystic Marriott Hotel & Spa . ... pathways individuals use to get into and sustain their recovery. Pathways of recovery are ...
(Date:5/27/2016)... ... 2016 , ... Southland Log Homes , designer and manufacturer of America’s ... which can be found on its website at SouthlandLogHomes.com. , The designs of the ... highlight the craftsmanship of timber post and beam construction. The result is a ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign ... inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also provides ... associations and industry leaders such as Bioness. , As patients feel increasingly ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... this installment is bolstered by inspiring human interest stories, courtesy of leaders in ... trends and tech within the industry, from leading advocates and associations—namely Jones & ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 Amarantus ... focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, ... will be presenting at two upcoming investor conferences: ... 730 Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand ...
(Date:5/26/2016)... , May 26, 2016   Change ... and analytics, network solutions and technology-enabled services ... it entered into a strategic channel partnership ... outpatient software solutions and revenue cycle management ... hospitals and rehabilitation clinics to optimize revenue, ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland , ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... agreement with Therawis Diagnostics GmbH to develop and commercialize predictive ... and market PITX2 as a marker to predict effectiveness of ... patients. "We are pleased to partner with Therawis, ...
Breaking Medicine Technology: